This HTML5 document contains 192 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n12http://dx.doi.org/10.1016/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q40040202
rdf:type
wikibase:Item
schema:description
2017年论文 2017年の論文 videnskabelig artikel мақолаи илмӣ مقالة علمية نشرت في 4 سبتمبر 2017 scienca artikolo naučni članak artículu científicu espublizáu en 2017 vedecký článok ৪ সেপ্টেম্বর ২০১৭-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ artikel ilmiah 2017년 논문 2017年論文 bilimsel makale artykuł naukowy tieteellinen artikkeli artikulong pang-agham teaduslik artikkel επιστημονικό άρθρο 2017年論文 2017年论文 scientific article published on 4 September 2017 artigo científico სამეცნიერო სტატია vědecký článek מאמר מדעי 2017年论文 wissenschaftlicher Artikel wetenschappelijk artikel наукова стаття, опублікована у вересні 2017 2017年論文 научни чланак научна статия scientific article published on 4 September 2017 บทความทางวิทยาศาสตร์ artigo científico 2017年论文 article científic 2017 nî lūn-bûn vitskapeleg artikkel articolo scientifico bài báo khoa học 2017年论文 2017年論文 vetenskaplig artikel научни чланак vitenskapelig artikkel tudományos cikk artikull shkencor 2017 թվականի սեպտեմբերի 4-ին հրատարակված գիտական հոդված article scientific 2017年论文 2017年論文 article scientifique научная статья scientific article published on 4 September 2017 artículo científico publicado en 2017 artigo científico articol științific
p:P577
wds:Q40040202-0C5107A2-4C96-455F-981A-7661500CC9F0
wdt:P577
2017-09-04T00:00:00Z
p:P407
wds:Q40040202-79851CA2-03FE-4AAC-B365-1F75CB8DB162
wdt:P407
wd:Q1860
p:P2860
wds:Q40040202-F5BACABE-AE7C-492B-B70B-AC08030CD2B1 wds:Q40040202-FF281476-8D63-487E-BAAF-B3557F72535D wds:Q40040202-DE9D307D-5E2A-4A6F-9DB3-D2E00783FC96 wds:Q40040202-DF164FAD-6C60-4892-847D-1E41589086AB wds:Q40040202-E8E20FFB-23E4-4BBF-B7CB-604C34CF0847 wds:Q40040202-C1FC2860-5957-4DE2-8E05-3BB05417A53B wds:Q40040202-C7552D8F-C3DC-4C30-9285-262E19A1FDF1 wds:Q40040202-C8AAFDAA-BEC9-4FDD-83F3-D4335238E42E wds:Q40040202-CE43A308-289A-4353-9747-DD4D036D34EC wds:Q40040202-A3C02569-B01B-43E8-8E5C-3474FD4DC220 wds:Q40040202-A9E09A71-4C4F-4FAA-ADB7-FA568896F1FD wds:Q40040202-B505AD6F-1985-455A-B9A8-DF1A657E5E39 wds:Q40040202-B722CDFC-238D-4A4C-AF54-418E0FC3B4B4 wds:Q40040202-619B195C-7C66-4947-B457-31028C084A6B wds:Q40040202-70656B25-329E-4B76-9DA3-154D2FD88711 wds:Q40040202-52B7D44F-BCB2-40C4-9AA9-EAC9ADC10B7D wds:Q40040202-577549E3-4979-4178-9458-6C8BFCDA0727 wds:Q40040202-60D70231-CC14-457D-B895-70884A96F92C wds:Q40040202-2A7945EC-7D35-40C8-8879-EC3C785E89D8 wds:Q40040202-2FA8A965-B926-4561-8622-153F22D311C1 wds:Q40040202-33A83475-A078-457B-8062-0A4ED5CCC9BC wds:Q40040202-4A758110-5B2A-43D0-B4F8-E37381BF9BD7 wds:Q40040202-4AB03897-077C-4F22-8853-3E164BBF81E6 wds:Q40040202-087DF44B-2767-4D97-B6B1-976A7D9A109A wds:Q40040202-08F69618-FB4F-43A1-AABF-AA46C3D3251F wds:Q40040202-13E7AFA1-8D0B-4BD0-BC76-C31FEE300880 wds:Q40040202-29582439-D716-4E6E-896B-9407520009CF wds:Q40040202-05535525-8536-49CB-95DB-295FA4494B82 wds:Q40040202-083E4929-3609-4019-9EE9-8926304E20AD
wdt:P2860
wd:Q38225681 wd:Q35616803 wd:Q46813619 wd:Q33442988 wd:Q33379886 wd:Q30439459 wd:Q83789859 wd:Q34317458 wd:Q38821916 wd:Q34435450 wd:Q36182023 wd:Q36478746 wd:Q84539941 wd:Q57569718 wd:Q53156124 wd:Q28131668 wd:Q41196227 wd:Q43161301 wd:Q33413862 wd:Q33420695 wd:Q57570904 wd:Q57570892 wd:Q44896083 wd:Q33370331 wd:Q33747406 wd:Q34580719 wd:Q84984963 wd:Q33342842 wd:Q51714855
p:P2093
wds:Q40040202-0912B4CC-ADDF-4CB5-8DAA-67871FF92570 wds:Q40040202-74ED5111-88CD-48A4-A5E8-30D9C28643D7 wds:Q40040202-615B22FA-91C7-4A33-91D7-965DE61B09F5 wds:Q40040202-58C04D45-81C8-464E-8D7C-546B4283B77F wds:Q40040202-52009673-71FE-4FB7-97EC-842B4AE8E8AE wds:Q40040202-4BF862C8-24B9-4BA7-92C0-C7F3CF3CBDE2 wds:Q40040202-50BB2CC3-5F21-4B9E-BF53-165FDBC9BB2C wds:Q40040202-D4185991-8606-41D8-A3CD-B10A6B72C053 wds:Q40040202-C34A94EE-2B1D-4E7B-A939-2B332142548F wds:Q40040202-C46AD0AA-5DD6-4494-9F2C-FC415C6CFA8A wds:Q40040202-B88C4D51-A167-40EC-84CC-E01B34252522 wds:Q40040202-FCA233C9-C5C8-4FC1-A8FC-D301EB4B795B wds:Q40040202-E27C4EB4-5879-40E9-821F-B2C0FB3C883C wds:Q40040202-D723F4A6-3C75-494C-BDCF-B95E1A5CB44A wds:Q40040202-38F52A87-F05E-4EE8-BD63-9B8A05BAC5E6 wds:Q40040202-28D1FAC9-A491-4B83-840C-AB01A857642F
wdt:P2093
Jeremy Whelan Sandy Beare Roberto Tirabosco Sandra J Strauss Sharon Forsyth Maria Marples Charlotte Benson Zoe Wood Katja Küver Beatrice Seddon Christian Rothermundt Stephen Nash Michael Leahy Hakim-Moulay Dehbi Nasim Ali Fiona Cowie
rdfs:label
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
skos:prefLabel
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
schema:name
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
p:P50
wds:Q40040202-5EE30DAC-B02A-4872-AED5-D5918CE6B4F4 wds:Q40040202-64682BF1-4CAC-47CB-991D-80CC7DCECFCD wds:Q40040202-81A036BB-94BF-4A93-B4E5-AE0A430EE48A
wdt:P50
wd:Q57474508 wd:Q56938488 wd:Q57001335
p:P1476
wds:Q40040202-9E7F20F6-2702-4DFB-90B5-1BEF5DCB4C4A
wdt:P1476
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
p:P304
wds:Q40040202-E5FD6F01-713A-49A1-BFEE-9BD709DE7778
wdt:P304
1397-1410
p:P31
wds:Q40040202-8FB8C580-99DF-4561-8E5E-6E23D32B2157
wdt:P31
wd:Q13442814
p:P921
wds:Q40040202-7D13C5E7-778A-412E-8DDA-B6DAE84C4AB8 wds:Q40040202-2CC00232-B651-4966-B526-ADD1952FEEA8 wds:Q40040202-8A70D880-8416-4B5D-A4A4-EE01C3C72EC3
wdt:P921
wd:Q42824827 wd:Q420436 wd:Q18936
p:P698
wds:Q40040202-459A9AD9-AE73-476B-BA9B-6E5EDB93BB8D
wdtn:P698
n4:28882536
wdt:P698
28882536
p:P1433
wds:Q40040202-FAE391DE-C76C-4F1A-A9E1-573682444C68
wdt:P1433
wd:Q13747613
p:P433
wds:Q40040202-F19D4B79-E9B9-4ECC-B281-9DD11E6A41AF
p:P478
wds:Q40040202-F50E0285-D9CF-4B67-AA1A-D86D9441B9B3
wdt:P433
10
wdt:P478
18
p:P356
wds:Q40040202-7183C1FE-DFAE-49C5-8BE4-D120B3982866
wdtn:P356
n12:S1470-2045(17)30622-8
wdt:P356
10.1016/S1470-2045(17)30622-8
p:P932
wds:Q40040202-14ED736B-6AE3-4B5A-A3E7-EA6D54A4512F
wdt:P932
5622179